
Labs in Court: Two EKRA-Related Cases and Some Usual Suspects
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
This Lab Institute presentation shares recent enforcement trends and how labs can avoid compliance risks related to these issues.
With the global cancer burden growing, is a universal germline genomic testing approach the key to more effectively combating the disease?
Recent advances in pharmacogenomic testing—and their role in ensuring safe, effective treatment selection for precision oncology
Direct-to-consumer (DTC) genetic testing has risen in popularity in recent years—but is it all it’s cracked up to be?